Melanotan 1, also known as afamelanotide, is a synthetic analog of α-melanocyte-stimulating hormone (α-MSH), the body's own signal for producing melanin — the pigment that gives skin its color and shields it from UV damage. The natural hormone is broken down quickly, so researchers redesigned it with two amino acid substitutions ([Nle4, D-Phe7]) to make a more stable, more potent version that holds its shape long enough to produce a meaningful biological effect.
The peptide works by binding the melanocortin-1 receptor (MC1R) on pigment-producing cells, switching on the machinery that builds eumelanin — the dark, photoprotective form of melanin. Because it triggers tanning through internal signaling rather than UV exposure, it's been studied as a way to darken skin and increase its natural sun protection without the DNA damage that comes from sunbathing.
What makes Melanotan 1 particularly interesting is that it appears to work even in people whose own melanin response is genetically weak — potentially the population that would benefit most from enhanced photoprotection.
Melanotan 1 and Skin Pigmentation
The clearest finding across the Melanotan 1 literature is that the peptide reliably increases skin melanin density. A randomized controlled trial in 77 individuals showed a highly significant increase (p<0.001) in melanin density in treated participants compared to placebo, measured directly in skin samples (1). The effect appeared across the test population rather than being confined to particular skin types.
An earlier clinical pharmacokinetic study tracking visible tanning over a ten-dose regimen found that pigmentation built gradually, peaked roughly a week after the last dose, and was still clearly present three weeks after dosing ended (2). This delayed-and-persistent pattern fits the underlying biology: the peptide signals melanocytes to ramp up melanin synthesis, and the pigment then accumulates and migrates outward as skin cells turn over, so the visible effect lags the actual signaling and outlasts the drug itself.
Melanotan 1 has a short circulating half-life — roughly 0.8 to 1.7 hours after subcutaneous dosing (2) — which means the tanning effect doesn't depend on continuous drug exposure but on a relatively brief activation of the pigment pathway.
Melanotan 1 and MC1R Genetic Variants
One of the more striking findings in the Melanotan 1 research concerns people with variant MC1R genes. MC1R is the receptor the peptide binds, and certain common variants (Val60Leu, Asp84Glu, Val92Met, Arg142His, Arg151Cys, Arg160Trp) reduce the receptor's signaling capacity. People carrying these variants tend to tan poorly, burn easily, and have higher skin cancer risk — they're the population that most needs photoprotection but whose biology resists providing it naturally.
In the controlled trial, individuals carrying these variant alleles actually showed greater increases in melanin density on Melanotan 1 than individuals with the standard MC1R sequence (1). The interpretation is that the peptide's high potency and prolonged binding may overcome the reduced signaling efficiency of variant receptors — essentially providing a strong enough push that even an underperforming receptor produces a meaningful melanin response. This is the opposite of what earlier in vitro work had predicted and suggests Melanotan 1 may be most effective in exactly the people who would benefit most from enhanced pigmentation.
Melanotan 1 and Routes of Administration
Pharmacokinetic work has clarified how Melanotan 1 needs to be delivered to work. A comparative trial dosing the peptide intravenously, orally, and subcutaneously found that subcutaneous administration was completely bioavailable relative to IV — meaning the same amount of peptide reached circulation either way (2). Oral dosing, by contrast, produced no detectable plasma levels at all, consistent with the peptide being broken down in the digestive tract before it can be absorbed.
Supporting laboratory work using the Caco-2 intestinal cell model and a validated HPLC assay confirmed limited transport across the gut barrier (3). Together these findings established subcutaneous injection as the practical route for research use, with both IV and SC producing comparable visible tanning while oral routes produce essentially no effect.